{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:25:57Z","timestamp":1793939157386,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Activated protein C (APC) is a plasma serine protease with antithrombotic and cytoprotective functions. Based on the hypothesis that specific inhibition of APC\u2019s anticoagulant but not its cytoprotective activity can be beneficial for hemophilia therapy, 2 types of inhibitory monoclonal antibodies (mAbs) are tested: A type I active-site binding mAb and a type II mAb binding to an exosite on APC (required for anticoagulant activity) as shown by X-ray crystallography. Both mAbs increase thrombin generation and promote plasma clotting. Type I blocks all APC activities, whereas type II preserves APC\u2019s cytoprotective function. In normal monkeys, type I causes many adverse effects including animal death. In contrast, type II is well-tolerated in normal monkeys and shows both acute and prophylactic dose-dependent efficacy in hemophilic monkeys. Our data show that the type II mAb can specifically inhibit APC\u2019s anticoagulant function without compromising its cytoprotective function and offers superior therapeutic opportunities for hemophilia.<\/jats:p>","DOI":"10.1038\/s41467-020-16720-9","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T10:03:06Z","timestamp":1591956186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia"],"prefix":"10.1038","volume":"11","author":[{"given":"Xiao-Yan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wilmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3136-8070","authenticated-orcid":false,"given":"Xinquan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine","family":"Bauzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Yun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Egner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Marquardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Moosmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Tebbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian Marius","family":"Gl\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Ellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanian","family":"Yegneswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vince","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ming","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornell","family":"Mallari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Hesslein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Gutberlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Ruehl-Fehlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexius","family":"Freyberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Hermiston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1195-964X","authenticated-orcid":false,"given":"Laurent O.","family":"Mosnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Laux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"16720_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","volume":"388","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi, F., Garagiola, I. & Young, G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet 388, 187\u2013197 (2016).","journal-title":"Lancet"},{"key":"16720_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1055\/s-2000-9821","volume":"26","author":"JM Lusher","year":"2000","unstructured":"Lusher, J. M. Inhibitor antibodies to factor VIII and factor IX: management. Semin. Thromb. Hemost. 26, 179\u2013188 (2000).","journal-title":"Semin. Thromb. Hemost."},{"key":"16720_CR3","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/ajh.24543","volume":"91","author":"J Hartmann","year":"2016","unstructured":"Hartmann, J. & Croteau, S. E. 2017 clinical trials update: innovations in hemophilia therapy. Am. J. Hematol. 91, 1252\u20131260 (2016).","journal-title":"Am. J. Hematol."},{"key":"16720_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00281-011-0284-6","volume":"34","author":"CT Esmon","year":"2012","unstructured":"Esmon, C. T. Protein C anticoagulant system-anti-inflammatory effects. Semin. Immunopathol. 34, 127\u2013132 (2012).","journal-title":"Semin. Immunopathol."},{"key":"16720_CR5","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1182\/blood-2015-02-355974","volume":"125","author":"JH Griffin","year":"2015","unstructured":"Griffin, J. H., Zlokovic, B. V. & Mosnier, L. O. Activated protein C: biased for translation. Blood 125, 2898\u20132907 (2015).","journal-title":"Blood"},{"key":"16720_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1182\/blood-2016-05-718635","volume":"129","author":"SG Polderdijk","year":"2017","unstructured":"Polderdijk, S. G. et al. Design and characterization of an APC-specific serpin for the treatment of hemophilia. Blood 129, 105\u2013113 (2017).","journal-title":"Blood"},{"key":"16720_CR7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1055\/s-0037-1615679","volume":"85","author":"C Escuriola Ettingshausen","year":"2001","unstructured":"Escuriola Ettingshausen, C. et al. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb. Haemost. 85, 218\u2013220 (2001).","journal-title":"Thromb. Haemost."},{"key":"16720_CR8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1046\/j.1365-2516.2001.00551.x","volume":"7","author":"F Vianello","year":"2001","unstructured":"Vianello, F. et al. Mild bleeding diathesis in a boy with combined severe haemophilia B (C(10400)->T) and heterozygous factor V Leiden. Haemophilia 7, 511\u2013514 (2001).","journal-title":"Haemophilia"},{"key":"16720_CR9","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood.V88.4.1183.bloodjournal8841183","volume":"88","author":"WC Nichols","year":"1996","unstructured":"Nichols, W. C. et al. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 88, 1183\u20131187 (1996).","journal-title":"Blood"},{"key":"16720_CR10","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/nm.2053","volume":"15","author":"J Xu","year":"2009","unstructured":"Xu, J. et al. Extracellular histones are major mediators of death in sepsis. Nat. Med. 15, 1318\u20131321 (2009).","journal-title":"Nat. Med."},{"key":"16720_CR11","doi-asserted-by":"publisher","first-page":"9251","DOI":"10.1074\/jbc.M610547200","volume":"282","author":"JS Bae","year":"2007","unstructured":"Bae, J. S., Yang, L., Manithody, C. & Rezaie, A. R. Engineering a disulfide bond to stabilize the calcium-binding loop of activated protein C eliminates its anticoagulant but not its protective signaling properties. J. Biol. Chem. 282, 9251\u20139259 (2007).","journal-title":"J. Biol. Chem."},{"key":"16720_CR12","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1182\/blood-2004-01-0110","volume":"104","author":"LO Mosnier","year":"2004","unstructured":"Mosnier, L. O., Gale, A. J., Yegneswaran, S. & Griffin, J. H. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood 104, 1740\u20131744 (2004).","journal-title":"Blood"},{"key":"16720_CR13","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.1182\/blood-2008-10-183327","volume":"113","author":"LO Mosnier","year":"2009","unstructured":"Mosnier, L. O. et al. Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood 113, 5970\u20135978 (2009).","journal-title":"Blood"},{"key":"16720_CR14","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2146\/ajhp080276","volume":"66","author":"HJ Mann","year":"2009","unstructured":"Mann, H. J., Short, M. A. & Schlichting, D. E. Protein C in critical illness. Am. J. Health Syst. Pharm. 66, 1089\u20131096 (2009).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"16720_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1182\/blood.V128.22.80.80","volume":"128","author":"XY Zhao","year":"2016","unstructured":"Zhao, X. Y. et al. Targeted inhibition of activated protein C anticoagulant activity by monoclonal antibody HAPC1573 for treatment of hemophilia (Abstract). Blood 128, 80 (2016).","journal-title":"Blood"},{"key":"16720_CR16","doi-asserted-by":"publisher","first-page":"6822","DOI":"10.1002\/j.1460-2075.1996.tb01073.x","volume":"15","author":"T Mather","year":"1996","unstructured":"Mather, T. et al. The 2.8 A crystal structure of Gla-domainless activated protein C. EMBO J. 15, 6822\u20136831 (1996).","journal-title":"EMBO J."},{"key":"16720_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1182\/blood.V96.2.585","volume":"96","author":"AJ Gale","year":"2000","unstructured":"Gale, A. J., Heeb, M. J. & Griffin, J. H. The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. Blood 96, 585\u2013593 (2000).","journal-title":"Blood"},{"key":"16720_CR18","doi-asserted-by":"crossref","first-page":"31869","DOI":"10.1016\/S0021-9258(18)31776-9","volume":"269","author":"M Kalafatis","year":"1994","unstructured":"Kalafatis, M., Rand, M. D. & Mann, K. G. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J. Biol. Chem. 269, 31869\u201331880 (1994).","journal-title":"J. Biol. Chem."},{"key":"16720_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S1050-1738(02)00191-3","volume":"13","author":"AR Rezaie","year":"2003","unstructured":"Rezaie, A. R. Exosite-dependent regulation of the protein C anticoagulant pathway. Trends Cardiovasc. Med. 13, 8\u201315 (2003).","journal-title":"Trends Cardiovasc. Med."},{"key":"16720_CR20","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1182\/blood-2013-03-488957","volume":"122","author":"L Burnier","year":"2013","unstructured":"Burnier, L. & Mosnier, L. O. Novel mechanisms for activated protein C cytoprotective activities involving noncanonical activation of protease-activated receptor 3. Blood 122, 807\u2013816 (2013).","journal-title":"Blood"},{"key":"16720_CR21","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.V92.2.496","volume":"92","author":"MG Jacquemin","year":"1998","unstructured":"Jacquemin, M. G. et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 92, 496\u2013506 (1998).","journal-title":"Blood"},{"key":"16720_CR22","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.4049\/jimmunol.1200090","volume":"188","author":"M Warncke","year":"2012","unstructured":"Warncke, M. et al. Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment. J. Immunol. 188, 4405\u20134411 (2012).","journal-title":"J. Immunol."},{"key":"16720_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/jth.12864","volume":"13","author":"P Chowdary","year":"2015","unstructured":"Chowdary, P. et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J. Thromb. Haemost. 13, 743\u2013754 (2015).","journal-title":"J. Thromb. Haemost."},{"key":"16720_CR24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nm.3847","volume":"21","author":"A Sehgal","year":"2015","unstructured":"Sehgal, A. et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat. Med. 21, 492\u2013497 (2015).","journal-title":"Nat. Med."},{"key":"16720_CR25","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1182\/blood-2017-09-800326","volume":"131","author":"Prince","year":"2018","unstructured":"Prince et al. Targeting anticoagulant protein S to improve hemostasis in hemophilia. Blood 131, 1360\u20131371 (2018).","journal-title":"Blood"},{"key":"16720_CR26","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/nm1498","volume":"12","author":"Cheng","year":"2006","unstructured":"Cheng et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat. Med. 12, 1278\u20131285 (2006).","journal-title":"Nat. Med."},{"key":"16720_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2018-02-769026","volume":"132","author":"JH Griffin","year":"2018","unstructured":"Griffin, J. H., Zlokovic, B. V. & Mosnier, L. O. Activated protein C, protease activated receptor 1, and neuroprotection. Blood 132, 159\u2013169 (2018).","journal-title":"Blood"},{"key":"16720_CR28","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1172\/JCI110385","volume":"68","author":"JH Griffin","year":"1981","unstructured":"Griffin, J. H., Evatt, B., Zimmerman, T. S., Kleiss, A. J. & Wideman, C. Deficiency of protein C in congenital thrombotic disease. J. Clin. Invest. 68, 1370\u20131373 (1981).","journal-title":"J. Clin. Invest."},{"key":"16720_CR29","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S0140-6736(83)91216-3","volume":"2","author":"HE Branson","year":"1983","unstructured":"Branson, H. E., Katz, J., Marble, R. & Griffin, J. H. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet 2, 1165\u20131168 (1983).","journal-title":"Lancet"},{"key":"16720_CR30","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/MOH.0000000000000364","volume":"24","author":"SGI Polderdijk","year":"2017","unstructured":"Polderdijk, S. G. I., Baglin, T. P. & Huntington, J. A. Targeting activated protein C to treat hemophilia. Curr. Opin. Hematol. 24, 446\u2013452 (2017).","journal-title":"Curr. Opin. Hematol."},{"key":"16720_CR31","doi-asserted-by":"publisher","first-page":"21158","DOI":"10.1074\/jbc.270.36.21158","volume":"270","author":"GA Nicolaes","year":"1995","unstructured":"Nicolaes, G. A. et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J. Biol. Chem. 270, 21158\u201321166 (1995).","journal-title":"J. Biol. Chem."},{"key":"16720_CR32","doi-asserted-by":"publisher","first-page":"23105","DOI":"10.1074\/jbc.M103138200","volume":"276","author":"U Friedrich","year":"2001","unstructured":"Friedrich, U., Nicolaes, G. A., Villoutreix, B. O. & Dahlback, B. Secondary substrate-binding exosite in the serine protease domain of activated protein C important for cleavage at Arg-506 but not at Arg-306 in factor Va. J. Biol. Chem. 276, 23105\u201323108 (2001).","journal-title":"J. Biol. Chem."},{"key":"16720_CR33","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/prot.10627","volume":"54","author":"AJ Gale","year":"2004","unstructured":"Gale, A. J. & Griffin, J. H. Characterization of a thrombomodulin binding site on protein C and its comparison to an activated protein C binding site for factor Va. Proteins 54, 433\u2013441 (2004).","journal-title":"Proteins"},{"key":"16720_CR34","doi-asserted-by":"publisher","first-page":"28836","DOI":"10.1074\/jbc.M204363200","volume":"277","author":"AJ Gale","year":"2002","unstructured":"Gale, A. J., Tsavaler, A. & Griffin, J. H. Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. J. Biol. Chem. 277, 28836\u201328840 (2002).","journal-title":"J. Biol. Chem."},{"key":"16720_CR35","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm.4154","volume":"22","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. 3K3A-activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice. Nat. Med 22, 1050\u20131055 (2016).","journal-title":"Nat. Med"},{"key":"16720_CR36","unstructured":"Zhao, X. Y., et al. Monoclonal antibodies against activated protein C (aPC). Patent Publication Number WO\/2014\/085596 A1 (2014)."},{"key":"16720_CR37","unstructured":"Zhao, X. Y., Wang, Z., Kim, J. Y., Zhu, Y. & Tebbe, J. Humanized monoclonal antibodies against activated protein C and uses thereof. Patent Publication Number WO\/2014\/085527 (2014)."},{"key":"16720_CR38","unstructured":"Zhao, X. Y., et al. Optimized humanized monoclonal antibodies against activated protein C and uses thereof. Patent Publication Number WO\/2015\/179435 (2015)."},{"key":"16720_CR39","doi-asserted-by":"crossref","unstructured":"O\u2019Brien S. and Jones T. Humanising Antibodies by CDR Grafting. in (eds Kontermann R., D\u00fcbel S.) Antibody Engineering. (Springer Lab Manuals. Springer, Berlin, Heidelberg, 2001).","DOI":"10.1007\/978-3-662-04605-0_40"},{"key":"16720_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ymeth.2005.01.004","volume":"36","author":"Hwang","year":"2005","unstructured":"Hwang et al. Use of human germline genes in a CDR homology-based approach to antibody humanization. Methods 36, 35\u201342 (2005).","journal-title":"Methods"},{"key":"16720_CR41","volume-title":"Expression Systems: Methods Express","author":"MR Dyson","year":"2007","unstructured":"Dyson, M. R. & Durocher, Y. Expression Systems: Methods Express. (Scion Publishing, Bloxham, UK, 2007)."},{"key":"16720_CR42","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"16720_CR43","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1107\/S0907444994003112","volume":"50","author":"Collaborative Computational Project Number 4.","year":"1994","unstructured":"Collaborative Computational Project Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D. Biol. Crystallogr. 50, 760\u2013763 (1994).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"16720_CR44","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"16720_CR45","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"16720_CR46","doi-asserted-by":"publisher","first-page":"33022","DOI":"10.1074\/jbc.M705824200","volume":"282","author":"LO Mosnier","year":"2007","unstructured":"Mosnier, L. O., Yang, X. V. & Griffin, J. H. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J. Biol. Chem. 282, 33022\u201333033 (2007).","journal-title":"J. Biol. Chem."},{"key":"16720_CR47","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1182\/blood-2012-08-452169","volume":"120","author":"LO Mosnier","year":"2012","unstructured":"Mosnier, L. O., Sinha, R. K., Burnier, L., Bouwens, E. A. & Griffin, J. H. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood 120, 5237\u20135246 (2012).","journal-title":"Blood"},{"key":"16720_CR48","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1021\/bi992357p","volume":"39","author":"L Shen","year":"2000","unstructured":"Shen, L., Dahlb\u00e4ck, B. & Villoutreix, B. O. Tracking structural features leading to resistance of activated protein C to alpha 1-antitrypsin. Biochemistry 39, 2853\u20132860 (2000).","journal-title":"Biochemistry"},{"key":"16720_CR49","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2014-07-585737","volume":"124","author":"A Muto","year":"2014","unstructured":"Muto, A. et al. Anti-factor IXa\/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood 124, 3165\u20133171 (2014).","journal-title":"Blood"},{"key":"16720_CR50","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1182\/blood-2012-08-452169","volume":"120","author":"LO Mosnier","year":"2012","unstructured":"Mosnier, L. O. et al. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood 120, 5237\u20135246 (2012).","journal-title":"Blood"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16720-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16720-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16720-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T23:16:53Z","timestamp":1670282213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16720-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["16720"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-16720-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"23 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: X.Y.Z., A.W., L.L., U.E., T.M., D.M., J.M.G., P.E., J.T., K.Mc.L., X.J., V.E., Y.X., A.H., V.L., N.S., Y.W.g, K.G., C.R.-F., and A.F. are employees of Bayer. J.-M.G., M.B., J.-Y.K., C.P., S.Y., D.S., Y.Z., S.Y., C.M., D.S., and T.H. were employees of Bayer at the time of the study. X.W., D.W., L.L., and L.M. received research funding from Bayer. X.W. is listed as a co-inventor of APC antibody patents filed by Bayer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2992"}}